Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Dopamine and Serotonin in HIV
NCT03581305Phase 1Completed
- Sponsor
- National Institutes of Health
- Start
- Nov 2018
- Primary completion
- Apr 2022
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of Fluorodopa F 18 and [11C]DASB in human immunodeficiency virus infection (HIV), HIV-associated neurocognitive disorder (HAND) and major depressive disorder (MDD) (2 arms), sponsored by National Institutes of Health. Primary endpoints: Influx Constant at 90 minutes and Binding Potential at 90 minutes. Started Nov 2018; status: completed.
02
Drugs
Fluorodopa F 18[11C]DASB
03
Conditions
human immunodeficiency virus infection (HIV)HIV-associated neurocognitive disorder (HAND)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03581305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03581305.